Payload Information
General Information of This Payload
| Payload ID | PAY0YCKCV |
|||||
|---|---|---|---|---|---|---|
| Name | AU2023281032A1 ADC-3 Payload |
|||||
| Synonyms |
AU2023281032A1 ADC-3 Payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C27H24FN3O7 |
|||||
| Isosmiles | CC[C@@]1(O)C(=O)OCC2=C1C=C1C3=NC4=CC(F)=C(O)C5=C4C(=C3CN1C2=O)[C@@H](NC(=O)C1(O)CC1)CC5 |
|||||
| InChI |
InChI=1S/C27H24FN3O7/c1-2-27(37)14-7-18-21-12(9-31(18)23(33)13(14)10-38-25(27)35)20-16(30-24(34)26(36)5-6-26)4-3-11-19(20)17(29-21)8-15(28)22(11)32/h7-8,16,32,36-37H,2-6,9-10H2,1H3,(H,30,34)/t16-,27-/m0/s1
|
|||||
| InChIKey |
VOOGWSIVQRHRJT-OQRWROFFSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
521.501 |
Polar area |
150.98 |
||
Complexity |
1646.255577 |
xlogp Value |
1.5527 |
|||
Heavy Count |
38 |
Rot Bonds |
3 |
|||
Hbond acc |
9 |
Hbond Donor |
4 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
AU2023281032A1 ADC-2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | maximum killing percentage |
39 nM
|
Negative TROP2 expression ( TROP2-) | ||
| Method Description |
the maximum killing percentage relative to the control group in MDA-MB-468
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | maximum killing percentage |
59.29 nM
|
Positive TROP2 expression (TROP2 +++/++) | ||
| Method Description |
the maximum killing percentage relative to the control group in HCC1954
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | maximum killing percentage |
65.17 nM
|
Positive TROP2 expression (TROP2 +++/++) | ||
| Method Description |
the maximum killing percentage relative to the control group in SK-BR-3
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.1076 nM
|
Positive TROP2 expression (TROP2 +++/++) | ||
| Method Description |
Proliferation Inhibition Action of Different Drugs on Tumor Cells (IC50, nM) in SK-BR-3
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.4355 nM
|
Positive TROP2 expression (TROP2 +++/++) | ||
| Method Description |
Proliferation Inhibition Action of Different Drugs on Tumor Cells (IC50, nM) in HCC1954
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
AU2023281032A1 ADC-3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.1928 nM
|
|||
| Method Description |
Proliferation Inhibition Action of Different Drugs on Tumor Cells (IC50, nM)in BxPC-3.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
References